Clinical and Experimental Pediatrics

Guideline

Infection

Recommendation for use of 15- and 20-valent pneumococcal conjugate vaccines in Korean infants and children

Ki Wook Yun, Dong Hyun Kim, Jong Gyun Ahn, Byung-Wook Eun, Jin Lee, Jina Lee, Taek-Jin Lee, Hyunju Lee, Dae Sun Jo, Eun Young Cho, Hye-Kyung Cho, Soo-Han Choi, Young June Choe, Ui Yoon Choi, Yun-Kyung Kim; The Committee on Infectious Diseases of the Korean Pediatric Society

Clin Exp Pediatr. 2026;69(1):76-83. Published online December 30, 2025

Compared to PCV13, PCV15 includes 2 (22F and 33F), and PCV20 includes 7 (8, 10A, 11A, 12F, 15B, 22F, and 33F) additional serotypes. The vaccination schedule remains the same: primary doses at 2, 4, and 6 months, and a booster at 12–15 months. If PCV13 was administered in the primary series, PCV15 and PCV20 may be used to complete it or as a booster.

DOI: https://doi.org/10.3345/cep.2025.01900

Original Article

Immunology

Immunogenicity and safety of a 12-valent pneumococcal conjugate vaccine in infants aged 6–10 weeks: a randomized double-blind active-controlled trial

Jonghoon Shin, Jamaree Teeratakulpisarn, Thanyawee Puthanakit, Tuangtip Theerawit, Ji Hwa Ryu, Jinhwan Shin, Seulgi Lee, Hayoung Lee, Kyungjun An, Hun Kim

Clin Exp Pediatr. 2020;63(7):265-271. Published online December 6, 2019

Web of Science 3 Crossref 2

Question: The immunogenicity and safety of GBP411 when administered to healthy infants are not understood.
Finding: The intergroup differences were not significant for all 12 serotypes after the booster dose. The overall incidence of solicited local adverse events between the groups did not differ significantly.
Meaning: GBP411 with a 2p+1 dosing schedule induced a substantial immune response, and may be safe for administration to healthy infants.

DOI: https://doi.org/10.3345/cep.2019.01067

Immune response to 19A serotype after immunization of 19F containing pneumococcal conjugate vaccine in Korean children aged 12-23 months

Hyun Ju Lee, So Eun Park, Kyung Hyo Kim

Clin Exp Pediatr. 2011;54(4):163-168. Published online April 30, 2011

Crossref 6

Purpose

The purpose of this study was to evaluate the immune response to serotype 19A in children aged 12-23 months after immunization of the 19F containing 7-valent pneumococcal conjugate vaccine (PCV7).

Methods

Blood samples from a total of 45 subjects (age 12-23 months) were included in the study. Subjects were categorized according to immunization status into three groups as follows: 18 subjects with...

DOI: https://doi.org/10.3345/kjp.2011.54.4.163

Review Article

Recommendation for use of the newly introduced pneumococcal protein conjugate vaccines in Korea

Eun Hwa Choi, Kyung Hyo Kim, Yae Jean Kim, Jong Hyun Kim, Su Eun Park, Hoan Jong Lee, Byung Wook Eun, Dae Sun Jo, Kyong Min Choi, Young Jin Hong

Clin Exp Pediatr. 2011;54(4):146-151. Published online April 30, 2011

Crossref 10

Streptococcus pneumoniae remains a leading cause of invasive infections including bacteremia and meningitis, as well as mucosal infections such as otitis media and pneumonia among children and adults. The 7-valent pneumococcal conjugate vaccine (PCV7) was licensed for use among infants and young children in many countries including Korea. The routine use of PCV7 has resulted in a decreased incidence of...

DOI: https://doi.org/10.3345/kjp.2011.54.4.146

Original Article

Serotypes and Penicillin Susceptibility of Streptococcus pneumoniae Isolated from Clinical Specimens and Healthy Carriers of Korean Children

Jin-A Lee, Nam-Hee Kim, Dong-Ho Kim, Ki-Won Park, Yun-Kyung Kim, Kyoung-Hyo Kim, Jin-Young Park, Eun-Hwa Choi, Hoan-Jong Lee

Clin Exp Pediatr. 2003;46(9):846-853. Published online September 15, 2003

Purpose : Pneumoccocus is one of the most important causes of invasive infection through the childhood period and the prevelance of antibiotics resistance of pneumococcus is increasing worldwide. A 7-valent conjugate vaccine has been developed. It is important to know the prevalence of each serotype of pneumococci in the countries where the vaccine is used to estimate the coverage rate...

PDF

Immunogenicity of Haemophilus influenzae PRP-D Conjugate Vaccine in Korean Infants

Soo Young Choi, Hee Taek Kim, Yeon Woo Kim, Yun Jong Kang, Yeon Chung Chung, Jin Keun Chang, Hoan Jong Lee

Clin Exp Pediatr. 1999;42(6):771-777. Published online June 15, 1999

Purpose : Infection by Haemophilus influenzae Type B(Hib) occurs most often in infants and children who are 5 years old and less. The incidence is highest around 6 months of age, and then decreases thereafter as infants gain natural immunity. Hi PRP-D conjugate vaccine is poorly immunogenic in infants. However, immunogenicity PRP-D vaccine in Korean infants is unknown. This...

PDF

Cited By 52	Prevalence of anxiety, depression, and stress among parents of neonates admitted to neonatal intensive care unit: a systematic review and meta-analysis
Cited By 35	Community-acquired pneumonia in children: updated perspectives on its etiology, diagnosis, and treatment
Cited By 33	Microplastic and human health with focus on pediatric well-being: a comprehensive review and call for future studies
Cited By 32	Metabolic complications of obesity in children and adolescents
Cited By 27	Neonatal family-centered care: evidence and practice models

Search